Research

Hormonal

Tirzepatide, a GLP-1/GIP receptor co-agonist, produces superior weight loss and glycemic control compared to selective GLP-1 receptor agonists and insulin in patients with type 2 diabetes.

If you have type 2 diabetes, tirzepatide is a once-weekly injection that lowers blood sugar and helps you lose more weight than older diabetes medications. It is generally well-tolerated, though you may experience gastrointestinal side effects. Discuss with your doctor if this once-weekly option is right for you.

GoodSupportsHIGH confidence
In subjects with T2DM, weekly administration of tirzepatide at doses of 5 mg, 10 mg, or 15 mg was associated with greater weight loss compared to placebo... and 1.7 kg, 4.8 kg, and 7.2 kg greater weight loss compared to selective GLP-1 receptor agonists, demonstrating a dose-dependent effect sustained for up to 2 years [48].
Stefano Ciardullo et al. · Acta Diabetologica · 2024

Why this rating

Based on multiple phase 3 randomized controlled trials (SURPASS, SURMOUNT) cited in the review.

Source

GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

Stefano Ciardullo et al. · Acta Diabetologica · 2024

DOI 10.1007/s00592-024-02300-6

narrative_reviewCited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →